The Elderly Multiple Myeloma Patient in the Era of Quad Therapy and CAR-T Cells
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 15 July 2025 | Viewed by 124
Special Issue Editors
Interests: multiple myeloma; CAR-T; cellular therapy
Special Issue Information
Dear Colleagues,
Multiple-myeloma therapy continues to evolve at a breakneck pace. Yearly, we are blessed with practice-changing clinical trials that change the treatment paradigm. Quadruplet induction and CAR-T cell therapy have improved clinical outcomes for new diagnosis and relapsed/refractory cases, respectively. The landmark clinical trial data have been recapitulated in multiple real-world datasets suggesting a generalizability of these findings. These regimens have very tolerable safety profiles, promoting deep clinical responses in both the “transplant-eligible” and the “transplant-ineligible” patient populations and may so fundamentally change our treatment paradigm that these designations may very well become a thing of the past.
As CAR-T and quadruplet therapies continue to gain new label indications, patient selection will become more important in clinical myeloma care. Despite the great outcomes with these agents, the medically frail patient remains challenging to treat. Indeed, while the landmark IMROZ trial included the “transplant-ineligible,” medically frail patients as well as patients > 80 years of age were excluded. While ide-cel , in general, has a more gentle side effect profile than cilta-cel, clinicians may be dissuaded from offering a CAR-T to an elderly patient and instead opt for a bispecific t-cell engager. Here, we invite you to share your expert opinion on the care of elderly and medically frail patients in the era of quadruplet induction and CAR-T cell therapy. By doing so, we hope to help inform clinical decision making that maximizes the therapeutic index of these interventions, helping to maintain a rigorous quality of life in these patients.
Dr. James J. Ignatz-Hoover
Prof. Dr. Koen Van Besien
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- quad therapy
- CAR-T
- elderly
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
